Temporal Trends and Racial Disparities in Renal Failure–Related Mortality Among Patients With Hematologic Cancers in the United States, 1999–2023

When a person is diagnosed with a cancer of the blood or bone marrow, the medical team's primary focus is naturally on eliminating the disease. Yet, the treatments designed to destroy these rogue cells can sometimes damage the body's own filtration system. The kidneys, which act as the body's internal water treatment plant, are particularly vulnerable. They must process the debris left behind when cancer cells are broken apart, the heavy load of medications used to fight the infection, and the metabolic chaos that often accompanies the illness itself. When these filters fail, a condition known as renal failure occurs, which can be fatal. For decades, doctors have known that this complication exists, but they have lacked a clear picture of how often it kills patients across the entire country, or whether the risk has changed as cancer treatments have improved. Understanding these patterns is crucial because it reveals who is most at risk and where the medical system is failing to protect its most vulnerable patients.

A team of researchers in the United States set out to map this hidden landscape of risk by looking at death records spanning twenty-five years. They examined data from nearly every adult in the country who died between 1999 and 2023 with a blood cancer listed as the primary cause of death and kidney failure recorded as a contributing factor. By analyzing over 120,000 such deaths, the team was able to track how the danger of kidney failure has shifted over time and across different groups of people. Their work reveals a story of slow progress followed by a worrying reversal, highlighting deep and persistent gaps in care that affect specific communities more than others.

The overall picture shows that the risk of dying from kidney failure among these patients has not changed drastically over the last quarter-century. When the researchers adjusted for the aging of the population, the rate of death per 100,000 people dropped only slightly, moving from 2.35 in 1999 to 2.06 in 2023. However, the journey between those two points was not a straight line. For a long stretch, the numbers were relatively flat, but then a significant drop occurred between 2012 and 2018. During those six years, the death rate fell sharply, suggesting that improvements in cancer care or better management of kidney health were making a real difference. But that progress did not last. Starting in 2018, the trend reversed, and the death rate began to climb again, rising through 2023. The researchers suggest this recent increase might not mean that treatments have become worse, but rather that patients are living longer with their cancer, accumulating years of exposure to medications and hospital stays that eventually take a toll on their kidneys. It is possible that the very success of extending life has created a new group of older survivors who are more fragile and susceptible to kidney damage later on.

The data also paints a stark picture of inequality based on gender, age, and race. Men consistently faced a much higher risk of dying from kidney failure than women, with death rates roughly double those of female patients. While both groups saw a decline in deaths for a time, the recent rise has been more pronounced among men. Age proved to be the single strongest predictor of risk. Older adults, those over 65, carried the overwhelming burden of these deaths, with rates far higher than those seen in middle-aged or young adults. This aligns with the understanding that kidneys naturally lose some of their filtering power as people age, making them less able to withstand the stress of cancer treatment.

Perhaps the most troubling finding concerns racial disparities. Throughout the entire twenty-five-year period, Black or African American patients faced the highest risk of death from kidney failure, with rates significantly higher than those of White, Hispanic, or Asian patients. Even as the overall numbers fluctuated, this gap remained stubbornly wide. The researchers point out that this disparity is likely not due to biology, but to systemic issues such as unequal access to specialized kidney care, differences in when patients are referred to specialists, and broader social factors that affect health. The fact that these gaps persist despite overall medical advances suggests that the problem lies in how care is delivered, not in the diseases themselves.

Geography also played a major role in determining who survived and who did not. The risk was not evenly distributed across the map. Patients in the West and Midwest regions generally faced higher death rates than those in the Northeast. When looking at individual states, the highest risks were found in places like North Dakota, Kentucky, and Nebraska, while states like New Mexico and New York had lower rates. The researchers noted that these differences often correlate with how easy it is to access dialysis centers and specialized cancer hospitals. Furthermore, people living in rural areas faced higher risks than those in cities, likely because of longer travel times to get to a hospital and a shortage of local specialists who can monitor kidney health closely.

The study also looked at where these deaths occurred, finding that the vast majority happened inside medical facilities like hospitals. This underscores that kidney failure in these patients is often an acute, severe event that requires immediate, intensive care. However, a significant portion of deaths also occurred at home or in hospice settings, indicating that for many, the end of life is managed outside the hospital walls.

Ultimately, this research serves as a reminder that while cancer treatments have advanced, the protection of the kidneys has not kept pace for everyone. The slight overall decline in death rates is overshadowed by the recent uptick and the deep inequalities that remain. The findings suggest that as patients live longer with blood cancers, the medical community must pay closer attention to their kidney health, particularly for older men, Black patients, and those living in rural areas. Without targeted efforts to close these gaps in care, the progress made in fighting cancer may be undermined by preventable kidney failure.